Overview
On 29 December 2000, orphan designation (EU/3/00/013) was granted by the European Commission to Laxdale Ltd., United Kingdom, for ethyl eicosopentaenoate for the treatment of Huntington's disease. The name of the sponsor has since changed to Amarin Neuroscience Ltd.
Key facts
Active substance |
Ethyl Eicosapentaenoate
|
Intended use |
Treatment of Huntington’s disease
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/00/013
|
Date of designation |
29/12/2000
|
Sponsor |
Amarin Neuroscience Ltd
Kings Park House Laurelhill Business Park STIRLING FK7 9JQ United Kingdom Telephone: +44 17 86 47 60 00 Telefax: +44 17 86 47 31 37 E-mail: admin@amarin-neuro.com |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: